Otonomy Inc
F:7OT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Southern Publishing and Media Co Ltd
SSE:601900
|
CN |
|
MSTC Ltd
NSE:MSTCLTD
|
IN |
|
Li-Cycle Holdings Corp
NYSE:LICY
|
CA |
Otonomy Inc
Total Assets
Otonomy Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Otonomy Inc
F:7OT
|
Total Assets
$57.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Assets
$199.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Assets
$90B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Assets
$208.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Assets
$136.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Assets
$112.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Otonomy Inc
Glance View
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
See Also
What is Otonomy Inc's Total Assets?
Total Assets
57.5m
USD
Based on the financial report for Sep 30, 2022, Otonomy Inc's Total Assets amounts to 57.5m USD.
What is Otonomy Inc's Total Assets growth rate?
Total Assets CAGR 5Y
-17%
Over the last year, the Total Assets growth was -45%. The average annual Total Assets growth rates for Otonomy Inc have been -14% over the past three years , -17% over the past five years .
